PROFOUND MEDICAL CORP (PROF)

CA74319B5027 - Common Stock

7.79  -0.11 (-1.39%)

Fundamental Rating

3

Taking everything into account, PROF scores 3 out of 10 in our fundamental rating. PROF was compared to 187 industry peers in the Health Care Equipment & Supplies industry. The financial health of PROF is average, but there are quite some concerns on its profitability. PROF is valued quite expensive, but it does show an excellent growth.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PROF has reported negative net income.
In the past year PROF has reported a negative cash flow from operations.
PROF had negative earnings in each of the past 5 years.
PROF had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

PROF has a worse Return On Assets (-74.32%) than 76.88% of its industry peers.
The Return On Equity of PROF (-101.05%) is worse than 64.52% of its industry peers.
Industry RankSector Rank
ROA -74.32%
ROE -101.05%
ROIC N/A
ROA(3y)-48.31%
ROA(5y)-43.25%
ROE(3y)-61.61%
ROE(5y)-62.59%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 62.02%, PROF is doing good in the industry, outperforming 62.90% of the companies in the same industry.
In the last couple of years the Gross Margin of PROF has grown nicely.
The Profit Margin and Operating Margin are not available for PROF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.57%
GM growth 5Y13.97%

More info and screens

5

2. Health

2.1 Basic Checks

PROF does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PROF has been increased compared to 1 year ago.
The number of shares outstanding for PROF has been increased compared to 5 years ago.
PROF has a worse debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 3.20 indicates that PROF is not in any danger for bankruptcy at the moment.
PROF has a Altman-Z score of 3.20. This is in the better half of the industry: PROF outperforms 67.74% of its industry peers.
PROF has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.12, PROF perfoms like the industry average, outperforming 58.06% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Altman-Z 3.2
ROIC/WACCN/A
WACC7.87%

2.3 Liquidity

PROF has a Current Ratio of 6.12. This indicates that PROF is financially healthy and has no problem in meeting its short term obligations.
PROF has a better Current ratio (6.12) than 83.87% of its industry peers.
PROF has a Quick Ratio of 5.16. This indicates that PROF is financially healthy and has no problem in meeting its short term obligations.
PROF has a Quick ratio of 5.16. This is amongst the best in the industry. PROF outperforms 82.26% of its industry peers.
Industry RankSector Rank
Current Ratio 6.12
Quick Ratio 5.16

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.60% over the past year.
Looking at the last year, PROF shows a very strong growth in Revenue. The Revenue has grown by 39.35%.
PROF shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 29.09% yearly.
EPS 1Y (TTM)3.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-46.15%
Revenue 1Y (TTM)39.35%
Revenue growth 3Y-0.48%
Revenue growth 5Y29.09%
Sales Q2Q%63.89%

3.2 Future

The Earnings Per Share is expected to grow by 23.56% on average over the next years. This is a very strong growth
PROF is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 80.07% yearly.
EPS Next Y12.47%
EPS Next 2Y14.92%
EPS Next 3Y16.63%
EPS Next 5Y23.56%
Revenue Next Year56.3%
Revenue Next 2Y101.93%
Revenue Next 3Y96.77%
Revenue Next 5Y80.07%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PROF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PROF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PROF's earnings are expected to grow with 16.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.92%
EPS Next 3Y16.63%

More info and screens

0

5. Dividend

5.1 Amount

PROF does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROFOUND MEDICAL CORP

NASDAQ:PROF (1/3/2025, 8:00:01 PM)

7.79

-0.11 (-1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners42.22%
Inst Owner Change-1.22%
Ins Owners9.14%
Ins Owner Change0%
Market Cap233.93M
Analysts83.33
Price Target14.83 (90.37%)
Short Float %1.36%
Short Ratio5.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.78%
Min EPS beat(2)-28.63%
Max EPS beat(2)5.06%
EPS beat(4)2
Avg EPS beat(4)-11.83%
Min EPS beat(4)-30.15%
Max EPS beat(4)6.39%
EPS beat(8)5
Avg EPS beat(8)-4.08%
EPS beat(12)8
Avg EPS beat(12)0.04%
EPS beat(16)8
Avg EPS beat(16)-5.75%
Revenue beat(2)0
Avg Revenue beat(2)-5.15%
Min Revenue beat(2)-7.61%
Max Revenue beat(2)-2.68%
Revenue beat(4)1
Avg Revenue beat(4)-10.49%
Min Revenue beat(4)-32.27%
Max Revenue beat(4)0.6%
Revenue beat(8)1
Avg Revenue beat(8)-19.92%
Revenue beat(12)2
Avg Revenue beat(12)-21.31%
Revenue beat(16)4
Avg Revenue beat(16)-19.93%
PT rev (1m)12%
PT rev (3m)22.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.83%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 26.04
P/FCF N/A
P/OCF N/A
P/B 7.53
P/tB 7.61
EV/EBITDA N/A
EPS(TTM)-1.34
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-0.83
FCFYN/A
OCF(TTM)-0.83
OCFYN/A
SpS0.3
BVpS1.03
TBVpS1.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -74.32%
ROE -101.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.02%
FCFM N/A
ROA(3y)-48.31%
ROA(5y)-43.25%
ROE(3y)-61.61%
ROE(5y)-62.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.57%
GM growth 5Y13.97%
F-Score4
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.12
Quick Ratio 5.16
Altman-Z 3.2
F-Score4
WACC7.87%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-46.15%
EPS Next Y12.47%
EPS Next 2Y14.92%
EPS Next 3Y16.63%
EPS Next 5Y23.56%
Revenue 1Y (TTM)39.35%
Revenue growth 3Y-0.48%
Revenue growth 5Y29.09%
Sales Q2Q%63.89%
Revenue Next Year56.3%
Revenue Next 2Y101.93%
Revenue Next 3Y96.77%
Revenue Next 5Y80.07%
EBIT growth 1Y-26.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.75%
EBIT Next 3Y29.67%
EBIT Next 5Y34.23%
FCF growth 1Y-1.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.45%
OCF growth 3YN/A
OCF growth 5YN/A